Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015

Authors Bok RA

Published 8 February 2008 Volume 2008:4(1) Pages 79—85

DOI https://doi.org/10.2147/TCRM.S905

Robert A Bok

Department of Radiology, University of California at San Francisco, San Francisco, CA, USA

Abstract: The body’s immune system has some capacity to recognize and attack cancerous growths, including prostate cancer. However, various intrinsic characteristics of tumor cells usually limit that capacity. Therapeutically administered immunologic stimuli, such as APC8015, an individualized, ex vivo stimulation of a patient’s own antigen presenting cells (APC), are capable of boosting the anti-tumor response. Late phase clinical trials of APC8015 (now also called Sipuleucel-T) show evidence of slowing disease progression and increasing survival in advanced prostate cancer. Such immunotherapeutic approaches hold real promise to provide additional useful and welcome weapons against this common malignancy.

Keywords: prostate cancer, antigen presenting cells, immunologics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Therapeutics and Clinical Risk Management 2008, 4:163-187

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

Teru Hideshima, Noopur Raje, Paul G Richardson, Kenneth C Anderson

Therapeutics and Clinical Risk Management 2008, 4:129-136

Published Date: 8 February 2008